Epigenetics in myeloid malignancies

Methods in Molecular Biology

Volumn 863, Issue , 2012, Pages 119-137

  Deneberg, Stefan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; DNA methylation; Histone modifications; Myelodysplastic syndromes

Indexed keywords

DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 3A; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

CPG ISLAND; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MUTATION; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PROGNOSIS; REVIEW;

CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS;

EID: 84859980073     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-612-8_7     Document Type: Review

References (106)

1. Baylin, S. B., Fearon, E. R., Vogelstein, B., de Bustros, A., Sharkis, S. J., Burke, P. J., Staal, S. P., and Nelkin, B. D. (1987) Hypermethylation of the 5 ¢ region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies, Blood 70 , 412-417. (Pubitemid 17142924)
2. Bacher, U., Haferlach, C., Schnittger, S., Kohlmann, A., Kern, W., and Haferlach, T. (2010) Mutations of the TET2 and CBL genes: Novel molecular markers in myeloid malignancies, Ann Hematol 89 , 643-652.
3. Lorsbach, R. B., Moore, J., Mathew, S., Raimondi, S. C., Mukatira, S. T., and Downing, J. R. (2003) TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11) (q22;q23), Leukemia 17 , 637-641. (Pubitemid 36395661)
4. Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., Liu, X. S., Aravind, L., Agarwal, S., Maciejewski, J. P., and Rao, A. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature 468 , 839-843.
5. Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., Lowenberg, B., Licht, J. D., Godley, L. A., Delwel, R., Valk, P. J., Thompson, C. B., Levine, R. L., and Melnick, A. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer Cell 18 , 553-567.
6. Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., Harris, C. C., Lichti, C. F., Townsend, R. R., Fulton, R. S., Dooling, D. J., Koboldt, D. C., Schmidt, H., Zhang, Q., Osborne, J. R., Lin, L., O'Laughlin, M., McMichael, J. F., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Magrini, V. J., Vickery, T. L., Hundal, J., Cook, L. L., Conyers, J. J., Swift, G. W., Reed, J. P., Alldredge, P. A., Wylie, T., Walker, J., Kalicki, J., Watson, M. A., Heath, S., Shannon, W. D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M. H., Link, D. C., Graubert, T. A., DiPersio, J. F., Mardis, E. R., and Wilson, R. K. (2010) DNMT3A mutations in acute myeloid leukemia, N Engl J Med 363 , 2424-2433.
7. Walker, H., Smith, F. J., and Betts, D. R. (1994) Cytogenetics in acute myeloid leukaemia, Blood Rev 8 , 30-36.
8. Mrozek, K., Heerema, N. A., and Bloomfield, C. D. (2004) Cytogenetics in acute leukemia, Blood Rev 18 , 115-136. (Pubitemid 38380667)
9. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., and Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties, Blood 92 , 2322-2333. (Pubitemid 28452973)
10. Dohner, K. and Dohner, H. (2008) Molecular characterization of acute myeloid leukemia, Haematologica 93 , 976-982. (Pubitemid 351957013)
11. Sanz, M., Burnett, A., Lo-Coco, F., and Lowenberg, B. (2009) FLT3 inhibition as a targeted therapy for acute myeloid leukemia, Curr Opin Oncol 21 , 594-600.
12. Christensen, B. C., Houseman, E. A., Marsit, C. J., Zheng, S., Wrensch, M. R., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Padbury, J. F., Bueno, R., Sugarbaker, D. J., Yeh, R. F., Wiencke, J. K., and Kelsey, K. T. (2009) Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context, PLoS Genet 5 , e1000602.
13. Ji, H., Ehrlich, L. I., Seita, J., Murakami, P., Doi, A., Lindau, P., Lee, H., Aryee, M. J., Irizarry, R. A., Kim, K., Rossi, D. J., Inlay, M. A., Serwold, T., Karsunky, H., Ho, L., Daley, G. Q., Weissman, I. L., and Feinberg, A. P. (2010) Comprehensive methylome map of lineage commitment from haematopoietic progenitors, Nature 467 , 338-342.
14. Plass, C., Oakes, C., Blum, W., and Marcucci, G. (2008) Epigenetics in acute myeloid leukemia, Semin Oncol 35 , 378-387.
15. Mahmud, M. and Stebbing, J. (2010) Epigenetic modifi cations in AML and MDS, Leuk Res 34 , 139-140.
16. Deneberg, S., Grovdal, M., Karimi, M., Jansson, M., Nahi, H., Corbacioglu, A., Gaidzik, V., Dohner, K., Paul, C., Ekstrom, T. J., Hellstrom-Lindberg, E., and Lehmann, S. (2010) Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia, Leukemia 24 , 932-941.
17. Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., Campagne, F., Mazumdar, M., Greally, J. M., Valk, P. J., Lowenberg, B., Delwel, R., and Melnick, A. (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia, Cancer Cell 17 , 13-27.
18. Melki, J. R., Warnecke, P., Vincent, P. C., and Clark, S. J. (1998) Increased DNA methyltransferase expression in leukaemia, Leukemia 12 , 311-316. (Pubitemid 28138214)
19. Gama-Sosa, M. A., Slagel, V. A., Trewyn, R. W., Oxenhandler, R., Kuo, K. C., Gehrke, C. W., and Ehrlich, M. (1983) The 5-methylcytosine content of DNA from human tumors, Nucleic Acids Res 11 , 6883-6894.
20. Ostler, K. R., Davis, E. M., Payne, S. L., Gosalia, B. B., Exposito-Cespedes, J., Le Beau, M. M., and Godley, L. A. (2007) Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins, Oncogene 26 , 5553-5563. (Pubitemid 47267842)
21. Ehrlich, M., Woods, C. B., Yu, M. C., Dubeau, L., Yang, F., Campan, M., Weisenberger, D. J., Long, T., Youn, B., Fiala, E. S., and Laird, P. W. (2006) Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors, Oncogene 25 , 2636-2645.
22. Jost, J. P., Oakeley, E. J., Zhu, B., Benjamin, D., Thiry, S., Siegmann, M., and Jost, Y. C. (2001) 5-Methylcytosine DNA glycosylase participates in the genome-wide loss of DNA methylation occurring during mouse myoblast differentiation, Nucleic Acids Res 29 , 4452-4461. (Pubitemid 33064786)
23. Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N. G., Perez-Rosado, A., Calvo, E., Lopez, J. A., Cano, A., Calasanz, M. J., Colomer, D., Piris, M. A., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T., and Esteller, M. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nat. Genet. 37 , 391-400.
24. Boland, C. R. and Goel, A. (2010) Microsatellite instability in colorectal cancer, Gastroenterology 138 , 2073-2087 e2073.
25. Nomdedeu, J. F., Perea, G., Estivill, C., Lasa, A., Carnicer, M. J., Brunet, S., Aventin, A., and Sierra, J. (2005) Microsatellite instability is not an uncommon fi nding in adult de novo acute myeloid leukemia, Ann Hematol 84 , 368-375. (Pubitemid 40823350)
26. Seedhouse, C. H., Das-Gupta, E. P., and Russell, N. H. (2003) Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia, Leukemia 17 , 83-88. (Pubitemid 36175892)
27. Toyota, M., Kopecky, K. J., Toyota, M. O., Jair, K. W., Willman, C. L., and Issa, J. P. (2001) Methylation profi ling in acute myeloid leukemia, Blood 97 , 2823-2829.
28. Rush, L. J., Dai, Z., Smiraglia, D. J., Gao, X., Wright, F. A., Fruhwald, M., Costello, J. F., Held, W. A., Yu, L., Krahe, R., Kolitz, J. E., Bloomfield, C. D., Caligiuri, M. A., and Plass, C. (2001) Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci, Blood 97 , 3226-3233.
29. Alvarez, S., Suela, J., Valencia, A., Fernandez, A., Wunderlich, M., Agirre, X., Prosper, F., Martin-Subero, J. I., Maiques, A., Acquadro, F., Rodriguez Perales, S., Calasanz, M. J., Roman-Gomez, J., Siebert, R., Mulloy, J. C., Cervera, J., Sanz, M. A., Esteller, M., and Cigudosa, J. C. (2010) DNA methylation profi les and their relationship with cytogenetic status in adult acute myeloid leukemia, PLoS One 5 , e12197.
30. Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. P., Silverman, L. B., Kutok, J. L., Kung, A. L., and Armstrong, S. A. (2008) H3K79 methylation profi les defi ne murine and human MLL-AF4 leukemias, Cancer Cell 14 , 355-368.
31. Rohrs, S., Dirks, W. G., Meyer, C., Marschalek, R., Scherr, M., Slany, R., Wallace, A., Drexler, H. G., and Quentmeier, H. (2009) Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia, Mol. Cancer 8 , 86.
32. Gaidzik, V. and Dohner, K. (2008) Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics, Semin. Oncol. 35 , 346-355.
33. Dorrance, A. M., Liu, S., Yuan, W., Becknell, B., Arnoczky, K. J., Guimond, M., Strout, M. P., Feng, L., Nakamura, T., Yu, L., Rush, L. J., Weinstein, M., Leone, G., Wu, L., Ferketich, A., Whitman, S. P., Marcucci, G., and Caligiuri, M. A. (2006) Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations, J. Clin. Invest 116 , 2707-2716. (Pubitemid 44511634)
34. Whitman, S. P., Hackanson, B., Liyanarachchi, S., Liu, S., Rush, L. J., Maharry, K., Margeson, D., Davuluri, R., Wen, J., Witte, T., Yu, L., Liu, C., Bloomfield, C. D., Marcucci, G., Plass, C., and Caligiuri, M. A. (2008) DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication, Blood 112 , 2013-2016.
35. Di Croce, L., Raker, V. A., Corsaro, M., Fazi, F., Fanelli, M., Faretta, M., Fuks, F., Lo Coco, F., Kouzarides, T., Nervi, C., Minucci, S., and Pelicci, P. G. (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor, Science 295 , 1079-1082. (Pubitemid 34132239)
36. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., Seiser, C., Lazar, M. A., Minucci, S., and Pelicci, P. G. (1998) Fusion proteins of the retinoic acid receptor-Alpha recruit histone deacetylase in promyelocytic leukaemia, Nature 391 , 815-818. (Pubitemid 28099683)
37. Villa, R., Pasini, D., Gutierrez, A., Morey, L., Occhionorelli, M., Vire, E., Nomdedeu, J. F., Jenuwein, T., Pelicci, P. G., Minucci, S., Fuks, F., Helin, K., and Di Croce, L. (2007) Role of the polycomb repressive complex 2 in acute promyelocytic leukemia, Cancer Cell 11 , 513-525. (Pubitemid 46863505)
38. Fazi, F., Zardo, G., Gelmetti, V., Travaglini, L., Ciolfi , A., Di Croce, L., Rosa, A., Bozzoni, I., Grignani, F., Lo-Coco, F., Pelicci, P. G., and Nervi, C. (2007) Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia, Blood 109 , 4432-4440. (Pubitemid 46743413)
39. Lugthart, S., Figueroa, M. E., Bindels, E., Skrabanek, L., Valk, P. J., Li, Y., Meyer, S., Erpelinck-Verschueren, C., Greally, J., Lowenberg, B., Melnick, A., and Delwel, R. (2010) Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1, Blood .
40. Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., Berman, D. M., Jenuwein, T., Pruitt, K., Sharkis, S. J., Watkins, D. N., Herman, J. G., and Baylin, S. B. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing, Nat. Genet. 39 , 237-242. (Pubitemid 46184356)
41. Paul, T. A., Bies, J., Small, D., and Wolff, L. (2010) Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML, Blood 115 , 3098-3108.
42. Zangenberg, M., Grubach, L., Aggerholm, A., Silkjaer, T., Juhl-Christensen, C., Nyvold, C. G., Kjeldsen, E., Ommen, H. B., and Hokland, P. (2009) The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML, Eur J Haematol 83 , 439-448.
43. Muller-Tidow, C., Klein, H. U., Hascher, A., Isken, F., Tickenbrock, L., Thoennissen, N., Agrawal-Singh, S., Tschanter, P., Disselhoff, C., Wang, Y., Becker, A., Thiede, C., Ehninger, G., Zur Stadt, U., Koschmieder, S., Seidl, M., Muller, F. U., Schmitz, W., Schlenke, P., McClelland, M., Berdel, W. E., Dugas, M., and Serve, H. (2010) Profi ling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia, Blood 116 , 3564-3571.
44. Grimwade, D., Vyas, P., and Freeman, S. (2010) Assessment of minimal residual disease in acute myeloid leukemia, Curr Opin Oncol 22 , 656-663.
45. Agrawal, S., Unterberg, M., Koschmieder, S., Stadt, U., Brunnberg, U., Verbeek, W., Buchner, T., Berdel, W. E., Serve, H., and Muller-Tidow, C. (2007) DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia, Cancer Res. 67 , 1370-1377.
46. Galm, O., Wilop, S., Luders, C., Jost, E., Gehbauer, G., Herman, J. G., and Osieka, R. (2005) Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia, Ann Hematol 84 Suppl 1 , 39-46.
47. Hess, C. J., Errami, A., Berkhof, J., Denkers, F., Ossenkoppele, G. J., Nygren, A. O., Schuurhuis, G. J., and Waisfi sz, Q. (2008) Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia, Leuk Lymphoma 49 , 1132-1141. (Pubitemid 351943260)
48. Li, Q., Kopecky, K. J., Mohan, A., Willman, C. L., Appelbaum, F. R., Weick, J. K., and Issa, J. P. (1999) Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia, Clin. Cancer Res. 5 , 1077-1084. (Pubitemid 29233222)
49. Shimamoto, T., Ohyashiki, J. H., and Ohyashiki, K. (2005) Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia, Leuk Res 29 , 653-659. (Pubitemid 40603565)
50. Bullinger, L., Ehrich, M., Dohner, K., Schlenk, R. F., Dohner, H., Nelson, M. R., and van den Boom, D. (2010) Quantitative DNA methylation predicts survival in adult acute myeloid leukemia, Blood 115 , 636-642.
51. Tormo, M., Marugan, I., and Calabuig, M. (2010) Myelodysplastic syndromes: An update on molecular pathology, Clin Transl Oncol 12 , 652-661.
52. Vardiman, J. W., Harris, N. L., and Brunning, R. D. (2002) The World Health Organization (WHO) classifi cation of the myeloid neoplasms, Blood 100 , 2292-2302.
53. Issa, J. P. (2010) Epigenetic changes in the myelodysplastic syndrome, Hematol Oncol Clin North Am 24 , 317-330.
54. Grovdal, M., Khan, R., Aggerholm, A., Antunovic, P., Astermark, J., Bernell, P., Engstrom, L. M., Kjeldsen, L., Linder, O., Nilsson, L., Olsson, A., Wallvik, J., Tangen, J. M., Oberg, G., Jacobsen, S. E., Hokland, P., Porwit, A., and Hellstrom-Lindberg, E. (2007) Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome, Clin. Cancer Res. 13 , 7107-7112. (Pubitemid 350276895)
55. Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., Kondo, Y., Oki, Y., Jelinek, J., Saba, H., Estey, E., and Issa, J. P. (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes, J. Clin. Oncol 28 , 605-613.
56. Rosu-Myles, M. and Wolff, L. (2008) p15Ink4b: Dual function in myelopoiesis and inactivation in myeloid disease, Blood Cells Mol Dis 40 , 406-409. (Pubitemid 351508443)
57. Aggerholm, A., Holm, M. S., Guldberg, P., Olesen, L. H., and Hokland, P. (2006) Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients, Eur J Haematol 76 , 23-32.
58. Au, W. Y., Fung, A., Man, C., Ma, S. K., Wan, T. S., Liang, R., and Kwong, Y. L. (2003) Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: Clinicopathological and karyotypic associations, Br J Haematol 120 , 1062-1065. (Pubitemid 36411568)
59. Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T., and Murate, T. (1997) Hypermethylation of the p15INK4B gene in myelodysplastic syndromes, Blood 90 , 1403-1409. (Pubitemid 27355412)
60. Quesnel, B., Guillerm, G., Vereecque, R., Wattel, E., Preudhomme, C., Bauters, F., Vanrumbeke, M., and Fenaux, P. (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression, Blood 91 , 2985-2990. (Pubitemid 28227550)
61. Herman, J. G., Civin, C. I., Issa, J. P., Collector, M. I., Sharkis, S. J., and Baylin, S. B. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies, Cancer Res. 57 , 837-841. (Pubitemid 27098005)
62. Figueroa, M. E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T. E., Paietta, E., Fernandez, H., Tallman, M. S., Greally, J. M., Carraway, H., Licht, J. D., Gore, S. D., and Melnick, A. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation, Blood 114 , 3448-3458.
63. Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., and Maciejewski, J. P. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML, Blood 113 , 1315-1325.
64. Kondo, Y. and Issa, J. P. (2004) Epigenetic changes in colorectal cancer, Cancer Metastasis Rev. 23 , 29-39. (Pubitemid 38221595)
65. Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., Dombret, H., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. L., and Silverman, L. R. (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia, J. Clin. Oncol 28 , 562-569.
66. Cashen, A. F., Schiller, G. J., O'Donnell, M. R., and DiPersio, J. F. (2010) Multicenter, phase II study of decitabine for the fi rst-line treatment of older patients with acute myeloid leukemia, J. Clin. Oncol 28 , 556-561.
67. Ravandi, F., Issa, J. P., Garcia-Manero, G., O'Brien, S., Pierce, S., Shan, J., Borthakur, G., Verstovsek, S., Faderl, S., Cortes, J., and Kantarjian, H. (2009) Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities, Cancer 115 , 5746-5751.
68. Raj, K., John, A., Ho, A., Chronis, C., Khan, S., Samuel, J., Pomplun, S., Thomas, N. S., and Mufti, G. J. (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-Azacytidine, Leukemia 21 , 1937-1944. (Pubitemid 47299967)
69. Itzykson, R., Thepot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., Delaunay, J., Salanoubat, C., Visanica, S., Stamatoullas, A., Isnard, F., Marfaing-Koka, A., de Botton, S., Chelghoum, Y., Taksin, A. L., Plantier, I., Ame, S., Boehrer, S., Gardin, C., Beach, C. L., Ades, L., and Fenaux, P. (2011) Prognostic factors of response and overall survival in 282 higher-risk myelodysplastic syndromes treated with azacitidine, Blood 117 , 403-411.
70. Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L., Mickle, J., Devine, H., Kefauver, C., Devine, S. M., Chan, K. K., Heerema, N. A., Bloomfield, C. D., Grever, M. R., Byrd, J. C., Villalona-Calero, M., Croce, C. M., and Marcucci, G. (2010) Clinical response and miR-29b predictive signifi cance in older AML patients treated with a 10-day schedule of decitabine, Proc. Natl. Acad. Sci. U S A 107 , 7473-7478.
71. Fandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S. H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., Licht, J., McConnell, M. J., Nasrallah, C., Kim, M. K., Zhang, W., Sun, Y., Murgo, A., Espinoza-Delgado, I., Oteiza, K., Owoeye, I., Silverman, L. R., Gore, S. D., and Carraway, H. E. (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-Azacytidine and entinostat in patients with myeloid malignancies, Blood 114 , 2764-2773.
72. Fenaux, P. and Ades, L. (2009) Review of azacitidine trials in Intermediate-2-And Highrisk myelodysplastic syndromes, Leuk Res 33 Suppl 2 , S7-11.
73. Keating, G. M. (2009) Azacitidine: A review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia, Drugs 69 , 2501-2518.
74. Hollenbach, P. W., Nguyen, A. N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S. L., Heise, C., and MacBeth, K. J. (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines, PLoS One 5 , e9001.
75. Xiong, J. and Epstein, R. J. (2009) Growth inhibition of human cancer cells by 5-Aza-2 -deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status, Mol. Cancer Ther 8 , 779-785.
76. Flotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C. M., and Lubbert, M. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells, Leukemia 23 , 1019-1028.
77. Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., and Gattermann, N. (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-Trans retinoic acid in patients with acute myeloid leukemia, Cancer 106 , 112-119. (Pubitemid 43032555)
78. Prebet, T. and Vey, N. (2010) Vorinostat in acute myeloid leukemia and myelodysplastic syndromes, Expert Opin Investig Drugs 20 , 287-295.
79. Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., Bonfi ls, C., Dubay, M., Patterson, T. A., Li, Z., Besterman, J. M., Reid, G., Laille, E., Martell, R. E., and Minden, M. (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia, Blood 112 , 981-989.
80. Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V. R., Randolph, S. S., Hardwick, J. S., Reilly, J. F., Chen, C., Ricker, J. L., Secrist, J. P., Richon, V. M., Frankel, S. R., and Kantarjian, H. M. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes, Blood 111 , 1060-1066. (Pubitemid 351213383)
81. Ungerstedt, J. S., Sowa, Y., Xu, W. S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., and Marks, P. A. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors, Proceedings of the National Academy of Sciences of the United States of America 102 , 673-678.
82. Barnes, D. J. and Melo, J. V. (2002) Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia, Acta Haematol 108 , 180-202. (Pubitemid 35356695)
83. Druker, B. J., O'Brien, S. G., Cortes, J., and Radich, J. (2002) Chronic myelogenous leukemia, Hematology Am Soc Hematol Educ Program 2002 , 111-135.
84. Tefferi, A. and Gilliland, D. G. (2005) The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classifi cation and diagnosis, Mayo Clin Proc 80 , 947-958. (Pubitemid 40911470)
85. Sawyers, C. L. (1999) Chronic myeloid leukemia, N Engl J Med 340 , 1330-1340. (Pubitemid 29196596)
86. Hochhaus, A. (2008) First-Line management of CML: A state of the art review, J Natl Compr Canc Netw 6 Suppl 2 , S1-S10. (Pubitemid 351871429)
87. Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J. A., Navarro, G., San Jose-Eneriz, E., Garate, L., Cordeu, L., Cervantes, F., Prosper, F., Heiniger, A., and Torres, A. (2008) Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia, Leuk Res 32 , 487-490. (Pubitemid 351308023)
88. Strathdee, G., Holyoake, T. L., Sim, A., Parker, A., Oscier, D. G., Melo, J. V., Meyer, S., Eden, T., Dickinson, A. M., Mountford, J. C., Jorgensen, H. G., Soutar, R., and Brown, R. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis, Clin. Cancer Res. 13 , 5048-5055. (Pubitemid 47502069)
89. Dunwell, T., Hesson, L., Rauch, T. A., Wang, L., Clark, R. E., Dallol, A., Gentle, D., Catchpoole, D., Maher, E. R., Pfeifer, G. P., and Latif, F. (2010) A genome-wide screen identifi es frequently methylated genes in haematological and epithelial cancers, Mol. Cancer 9 , 44.
90. Chim, C. S., Wong, K. Y., Leung, C. Y., Chung, L. P., Hui, P. K., Chan, S. Y., and Yu, L. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies, J Cell Mol Med .
91. Chim, C. S., Wong, K. Y., Qi, Y., Loong, F., Lam, W. L., Wong, L. G., Jin, D. Y., Costello, J. F., and Liang, R. (2010) Epigenetic inactivation of the miR-34a in hematological malignancies, Carcinogenesis 31 , 745-750.
92. Strathdee, G., Ferguson, S., Sim, A., and Brown, R. DNA methylation does not regulate JUNB expression in CML: Comment on "Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia" by Hoshino et al. [Leuk. Res. 33 (2009) 1361-1366], Leuk Res 34 , 685-686.
93. Uhm, K. O., Lee, E. S., Lee, Y. M., Park, J. S., Kim, S. J., Kim, B. S., Kim, H. S., and Park, S. H. (2009) Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia, J Korean Med Sci 24 , 493-497.
94. Wang, Y. L., Qian, J., Lin, J., Yao, D. M., Qian, Z., Zhu, Z. H., and Li, J. Y. (2010) Methylation status of DDIT3 gene in chronic myeloid leukemia, J Exp Clin. Cancer Res. 29 , 54.
95. Ohyashiki, J. H., Ohyashiki, K., Kawakubo, K., Tauchi, T., Shimamoto, T., and Toyama, K. (1993) The methylation status of the major breakpoint cluster region in human leukemia cells, including Philadelphia chromosomepositive cells, is linked to the lineage of hematopoietic cells, Leukemia 7 , 801-807.
96. Mizuno, S., Chijiwa, T., Okamura, T., Akashi, K., Fukumaki, Y., Niho, Y., and Sasaki, H. (2001) Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia, Blood 97 , 1172-1179.
97. Asimakopoulos, F. A., Shteper, P. J., Krichevsky, S., Fibach, E., Polliack, A., Rachmilewitz, E., Ben-Neriah, Y., and Ben-Yehuda, D. (1999) ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia, Blood 94 , 2452-2460. (Pubitemid 29467694)
98. Issa, J. P., Kantarjian, H., Mohan, A., O'Brien, S., Cortes, J., Pierce, S., and Talpaz, M. (1999) Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic signifi cance, Blood 93 , 2075-2080. (Pubitemid 29128511)
99. San Jose-Eneriz, E., Agirre, X., Jimenez-Velasco, A., Cordeu, L., Martin, V., Arqueros, V., Garate, L., Fresquet, V., Cervantes, F., Martinez-Climent, J. A., Heiniger, A., Torres, A., Prosper, F., and Roman-Gomez, J. (2009) Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia, Eur J Cancer 45 , 1877-1889.
100. Fiskus, W., Wang, Y., Joshi, R., Rao, R., Yang, Y., Chen, J., Kolhe, R., Balusu, R., Eaton, K., Lee, P., Ustun, C., Jillella, A., Buser, C. A., Peiper, S., and Bhalla, K. (2008) Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells, Clin. Cancer Res. 14 , 6106-6115.
101. Bixby, D. and Talpaz, M. (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance, Hematology Am Soc Hematol Educ Program 2009 , 461-476.
102. Lee, S. M., Bae, J. H., Kim, M. J., Lee, H. S., Lee, M. K., Chung, B. S., Kim, D. W., Kang, C. D., and Kim, S. H. (2007) Bcr-Ablindependent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors, J Pharmacol Exp Ther 322 , 1084-1092.
103. Zhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K. D., Snyder, D. S., Huettner, C. S., Shultz, L., Holyoake, T., and Bhatia, R. (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate, Cancer Cell 17 , 427-442.
104. Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Issa, J. P., Garcia-Manero, G., Rios, M. B., Shan, J., Andreeff, M., Keating, M., and Talpaz, M. (2003) Results of decitabine (5-Aza-2 ¢ deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia, Cancer 98 , 522-528. (Pubitemid 36885992)
105. Ekmekci, C. G., Gutierrez, M. I., Siraj, A. K., Ozbek, U., and Bhatia, K. (2004) Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia, Am. J. Hematol 77 , 233-240. (Pubitemid 39430701)
106. Kroeger, H., Jelinek, J., Estecio, M. R., He, R., Kondo, K., Chung, W., Zhang, L., Shen, L., Kantarjian, H. M., Bueso-Ramos, C. E., and Issa, J. P. (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse, Blood 112 , 1366-1373.